Clinical Impact of the 2016 Update to the WHO Lymphoma Classification
- PMID: 28670664
- DOI: 10.1007/s11864-017-0483-z
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification
Erratum in
-
Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Curr Treat Options Oncol. 2017 Oct;18(10):60. doi: 10.1007/s11864-017-0499-4. Curr Treat Options Oncol. 2017. PMID: 28861885 No abstract available.
Abstract
The 2016 revision of the WHO classification of lymphoid neoplasms includes new entities along with a clearer definition of provisional and definitive subtypes based on better understanding of the molecular drivers of lymphomas. These changes impact current treatment paradigms and provide a framework for future clinical trials. Additionally, this update recognizes several premalignant or predominantly indolent entities and underscores the importance of avoiding unnecessarily aggressive treatment in the latter subsets.
Keywords: ALK-negative anaplastic large cell lymphoma (ALCL); BCL6 translocations; Burkitt lymphoma; Chronic lymphocytic leukemia (CLL); Diffuse large B cell lymphoma (DLBCL); Double hit lymphoma; Follicular lymphoma; High grade B cell lymphoma NOS; Lymphoplasmacytic lymphoma; Mantle cell lymphoma; Non-Hodgkin lymphoma; Waldenström macroglobulinemia.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
